We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.83%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$434M
AUM Growth
+$154M
Cap. Flow
+$130M
Cap. Flow %
30.03%
Top 10 Hldgs %
39.11%
Holding
88
New
19
Increased
48
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$23.2M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.04M
3
ABBV icon
AbbVie
ABBV
+$6.82M
4
ITMN
INTERMUNE INC
ITMN
+$6.35M
5
AGN
Allergan plc
AGN
+$6.29M

Top Sells

Rank Stock Value
1
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$9.8M
2
GENT
GENTIUM SPA ADS
GENT
+$6.82M
3
AET
Aetna Inc
AET
+$4.27M
4
PBYI icon
Puma Biotechnology
PBYI
+$3.26M
5
EW icon
Edwards Lifesciences
EW
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 79.37%
2 Industrials 1.53%
3 Technology 0.49%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$640B
$24.6M 5.66%
+250,000
New +$23.2M
GILD icon
2
Gilead Sciences
GILD
$165B
$23.5M 5.41%
331,000
+46,000
+16% +$3.61M
ABBV icon
3
AbbVie
ABBV
$465B
$18.5M 4.27%
360,000
+135,000
+60% +$6.82M
BIIB icon
4
Biogen
BIIB
$30.9B
$16.9M 3.9%
55,250
+2,250
+4% +$714K
MCK icon
5
McKesson
MCK
$104B
$16.2M 3.73%
91,500
+28,500
+45% +$4.98M
UNH icon
6
UnitedHealth
UNH
$382B
$14.8M 3.42%
181,000
+81,000
+81% +$6.1M
THOR
7
DELISTED
THORATEC CORPORATION
THOR
$14.4M 3.31%
401,000
+126,000
+46% +$4.52M
AMGN icon
8
Amgen
AMGN
$209B
$14.2M 3.27%
115,000
+36,000
+46% +$4.37M
ITMN
9
DELISTED
INTERMUNE INC
ITMN
$13.7M 3.17%
410,000
+285,000
+228% +$6.35M
TMO icon
10
Thermo Fisher Scientific
TMO
$214B
$12.9M 2.97%
107,250
+39,750
+59% +$4.73M
XLV icon
11
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
$11.7M 2.7%
200,000
-170,000
-46% -$9.8M
AGN
12
DELISTED
Allergan plc
AGN
$11.6M 2.67%
56,250
+31,750
+130% +$6.29M
CELG
13
DELISTED
Celgene Corp
CELG
$10.7M 2.48%
154,000
+30,000
+24% +$2.38M
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$10.1M 2.32%
+750,000
New +$8.04M
BMY icon
15
Bristol-Myers Squibb
BMY
$129B
$9.64M 2.22%
185,500
+5,000
+3% +$266K
A icon
16
Agilent Technologies
A
$39.6B
$8.67M 2%
216,690
+30,756
+17% +$1.27M
CVS icon
17
CVS Health
CVS
$135B
$8.46M 1.95%
113,000
+58,250
+106% +$4.11M
COO icon
18
Cooper Companies
COO
$14.2B
$8.31M 1.92%
242,000
+176,000
+267% +$5.65M
ISRG icon
19
Intuitive Surgical
ISRG
$127B
$8.1M 1.87%
166,500
+9,000
+6% +$424K
HUM icon
20
Humana
HUM
$43.9B
$7.38M 1.7%
65,500
+32,500
+98% +$3.39M
ALXN
21
DELISTED
Alexion Pharmaceuticals
ALXN
$7.38M 1.7%
48,500
-2,500
-5% -$398K
BHC icon
22
Bausch Health
BHC
$1.75B
$6.99M 1.61%
53,000
+6,000
+13% +$820K
ILMN icon
23
Illumina
ILMN
$29.5B
$6.32M 1.46%
43,690
-13,107
-23% -$1.93M
TMH
24
DELISTED
Team Health Holdings Inc
TMH
$5.43M 1.25%
121,250
+3,750
+3% +$169K
OREX
25
DELISTED
Orexigen Therapeutics, Inc.
OREX
$5.39M 1.24%
83,000
+30,500
+58% +$2.06M
1
2 3 4

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rock Springs Capital Management held 88 positions worth $434M, up 55% from $280M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Rock Springs Capital Management deployed $130M of net new capital in Q1 2014, opening 19 new positions and adding to 48 existing holdings. Its largest new stake was Johnson & Johnson: 250,000 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was State Street Health Care Select Sector SPDR ETF, an estimated $9.8M trimmed.

  • Rock Springs Capital Management's largest Q1 2014 buy was Johnson & Johnson: 250,000 shares worth $24.6M.
  • Rock Springs Capital Management added most to AbbVie in Q1 2014, an estimated $6.82M increase.
  • Rock Springs Capital Management's biggest Q1 2014 reduction was State Street Health Care Select Sector SPDR ETF, cutting an estimated $9.8M.
  • Rock Springs Capital Management fully exited GENTIUM SPA ADS in Q1 2014, selling an estimated $6.82M.
  • Rock Springs Capital Management's ten largest holdings make up 39% of its $434M portfolio in Q1 2014.
  • Rock Springs Capital Management opened 19 new positions and closed 13 in Q1 2014.
  • Rock Springs Capital Management's portfolio value rose 55% quarter-over-quarter to $434M.

Based on Rock Springs Capital Management's 13F filing for Q1 2014, filed 15 May 2014.